ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that Dr. Carl Firth, CEO, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 09:00 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that Dr. Carl Firth, CEO, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 09:00 am ET. The event runs from August 9 to August 10, 2021. ASLAN is focused on developing innovative treatments for patients with clinical-stage immunology. The company is advancing ASLAN004, targeting IL-13 for atopic dermatitis, and ASLAN003, an oral inhibitor for autoimmune diseases. More details are available on their website.
Details
News Market Reaction – ASLN
The recorded move for ASLN in the trading session of this news was -2.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SINGAPORE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 09:00 am ET. The conference will be held from August 9 to August 10, 2021.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in the Bay Area and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.